These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 20624837

  • 1. Exenatide therapy in insulin-treated type 2 diabetes and obesity.
    Nayak UA, Govindan J, Baskar V, Kalupahana D, Singh BM.
    QJM; 2010 Sep; 103(9):687-94. PubMed ID: 20624837
    [Abstract] [Full Text] [Related]

  • 2. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
    Sheffield CA, Kane MP, Busch RS.
    Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
    [Abstract] [Full Text] [Related]

  • 3. Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus.
    Paisley AN, Savage MW, Wiles PG.
    Diabet Med; 2009 Sep; 26(9):935-8. PubMed ID: 19719716
    [Abstract] [Full Text] [Related]

  • 4. Use of exenatide for weight loss in patients with diabetes.
    Virji A.
    Am Fam Physician; 2007 May 01; 75(9):1304. PubMed ID: 17511061
    [No Abstract] [Full Text] [Related]

  • 5. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
    Gallwitz B.
    Int J Clin Pract; 2006 Dec 01; 60(12):1654-61. PubMed ID: 17109672
    [Abstract] [Full Text] [Related]

  • 6. Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy.
    Segal JB, Dy SM, Millman EA, Herbert R, Bass EB, Wu A.
    Clin Ther; 2007 Aug 01; 29(8):1784-94. PubMed ID: 17919559
    [Abstract] [Full Text] [Related]

  • 7. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
    Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K.
    Diabetes Care; 2007 Jun 01; 30(6):1487-93. PubMed ID: 17353504
    [Abstract] [Full Text] [Related]

  • 8. Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy.
    Pawaskar MD, Blickensderfer AL, Hoogwerf BJ, Quimbo R, Wade R.
    J Med Econ; 2011 Jun 01; 14(6):705-8. PubMed ID: 21892855
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting.
    Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G.
    Diabetes Obes Metab; 2009 Nov 01; 11(11):1068-79. PubMed ID: 19732121
    [Abstract] [Full Text] [Related]

  • 10. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR, Cha R, Brown MB, Jaber LA.
    Ann Pharmacother; 2008 Nov 01; 42(11):1541-51. PubMed ID: 18957626
    [Abstract] [Full Text] [Related]

  • 11. Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population.
    Rashid N, McCombs JS, Schwartz E.
    Clin Ther; 2012 May 01; 34(5):1145-58. PubMed ID: 22464691
    [Abstract] [Full Text] [Related]

  • 12. Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series.
    Kenny PR, Brady DE, Torres DM, Ragozzino L, Chalasani N, Harrison SA.
    Am J Gastroenterol; 2010 Dec 01; 105(12):2707-9. PubMed ID: 21131943
    [No Abstract] [Full Text] [Related]

  • 13. Exenatide and acute pancreatitis.
    Tripathy NR, Basha S, Jain R, Shetty S, Ramachandran A.
    J Assoc Physicians India; 2008 Dec 01; 56():987-8. PubMed ID: 19322980
    [Abstract] [Full Text] [Related]

  • 14. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes.
    Ghofaili KA, Fung M, Ao Z, Meloche M, Shapiro RJ, Warnock GL, Elahi D, Meneilly GS, Thompson DM.
    Transplantation; 2007 Jan 15; 83(1):24-8. PubMed ID: 17220786
    [Abstract] [Full Text] [Related]

  • 15. [Incretin-mimetic drugs, an insulin alternative in type 2 diabetes].
    Fabreegas B.
    Soins; 2008 Jun 15; (726):34-7. PubMed ID: 18697336
    [No Abstract] [Full Text] [Related]

  • 16. Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment.
    Al-Jebawi AF.
    Diabetes Res Clin Pract; 2010 Dec 15; 90(3):e88-90. PubMed ID: 21030101
    [Abstract] [Full Text] [Related]

  • 17. Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting.
    Bergenstal RM, Garrison LP, Wintle M, Blickensderfer A, Wade R, Hou L, Miller LA, Scism-Bacon J, Zagar A, Misurski D, Herman WH.
    Curr Med Res Opin; 2011 Mar 15; 27(3):531-40. PubMed ID: 21219119
    [Abstract] [Full Text] [Related]

  • 18. Incretins and other peptides in the treatment of diabetes.
    Todd JF, Bloom SR.
    Diabet Med; 2007 Mar 15; 24(3):223-32. PubMed ID: 17263764
    [Abstract] [Full Text] [Related]

  • 19. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes.
    Okerson T, Yan P, Stonehouse A, Brodows R.
    Am J Hypertens; 2010 Mar 15; 23(3):334-9. PubMed ID: 20019672
    [Abstract] [Full Text] [Related]

  • 20. Exenatide (Byetta) for type 2 diabetes.
    Med Lett Drugs Ther; 2005 Jun 06; 47(1210):45-6. PubMed ID: 15933616
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.